Is gabapentin (Neurontin) addictive, particularly in individuals with a history of substance abuse?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Gabapentin Addictive?

Yes, gabapentin has documented addiction potential, particularly in individuals with a history of substance use disorders, though its addictive power in the general population without prior substance abuse history is relatively low. 1, 2

Risk Profile by Patient Population

High-Risk Patients (History of Substance Use Disorder)

  • All documented cases of gabapentin addiction occurred in patients with previous histories of alcohol, cocaine, or opioid abuse. 3
  • In drug abuse treatment centers, gabapentin misuse rates reach 22%, compared to only 1.1% in the general population. 3
  • Patients with opioid use disorders are at particularly elevated risk for gabapentinoid abuse. 4
  • In these high-risk populations, gabapentin should be avoided or, if indispensable, administered with strict therapeutic and prescription monitoring. 2, 5

General Population (No Substance Use History)

  • Only 4 documented cases worldwide show behavioral dependence on gabapentinoids in patients without prior substance use disorder history—all involving pregabalin, none for gabapentin. 5
  • There are no published reports of patients seeking detoxification treatment specifically for gabapentinoid misuse. 5
  • The limited rewarding properties and very few cases of behavioral dependence symptoms suggest gabapentin lacks vigorous addictive power in this population. 2

Physical Dependence vs. Addiction

Physical Dependence Characteristics

  • Approximately 50% of patients prescribed gabapentinoids continuously for at least 12 months may develop physical dependence. 6, 7
  • Withdrawal symptoms occur within 12 hours to 7 days after abrupt discontinuation. 3
  • Withdrawal manifestations include agitation, disorientation, confusion, severe anxiety, low mood, and somatic symptoms. 6, 1
  • Physical dependence is distinct from addiction—it represents neuroadaptation, not necessarily compulsive drug-seeking behavior. 8

Behavioral Dependence (True Addiction)

  • Behavioral dependence symptoms (craving, loss of control, drug-seeking behavior) are far less common than physical dependence. 5
  • Patients typically take doses exceeding 3000 mg/day (range 600-8000 mg/day) when abusing gabapentin. 3
  • Signs of misuse include development of tolerance, self-dose escalation, and drug-seeking behavior. 1

Critical Safety Concern: Opioid Co-Administration

When gabapentin is combined with opioids, dangerous synergistic respiratory depression occurs, significantly increasing overdose risk and opioid-related mortality. 7, 8

  • This interaction is similar to the lethal benzodiazepine-opioid combination. 7
  • Gabapentin is commonly abused specifically to potentiate opioid effects. 7
  • Pure gabapentin overdoses are relatively safe, but become potentially lethal when mixed with opioids or sedatives. 2
  • Prescribers must be vigilant about concurrent opioid prescriptions and review prescription drug monitoring programs (PDMPs) before prescribing. 7

Clinical Management Recommendations

Before Prescribing

  • Carefully evaluate all patients for history of drug abuse using validated risk assessment tools, though this is not an absolute contraindication. 1, 7
  • Check PDMP for concurrent controlled substance prescriptions and patterns of doctor shopping. 7
  • Avoid gabapentin in patients with current or past substance use disorders when possible. 2, 4

During Treatment

  • Monitor for signs of misuse: tolerance development, self-dose escalation, drug-seeking behavior. 1
  • Be especially cautious with patients on concurrent opioids due to respiratory depression risk. 7, 8
  • Long-term prescribing beyond 12 months increases dependence risk and often lacks evidence of continued efficacy. 6

Discontinuation

  • Never abruptly discontinue gabapentin in patients on long-term therapy—taper slowly to prevent withdrawal symptoms. 7, 8
  • Offer careful tapering support and monitoring for withdrawal manifestations. 8
  • Patients who suddenly stop higher-than-recommended doses may experience severe withdrawal requiring gabapentin reinitiation. 1

Regulatory Status

Several jurisdictions have designated gabapentin as a controlled substance due to documented abuse potential, dependence, withdrawal symptoms, and increased opioid-related mortality when combined with opioids. 7 However, the FDA does not classify gabapentin as a federally scheduled controlled substance. 1

Common Pitfall to Avoid

Do not dismiss patient reports of withdrawal symptoms as merely indicating relapse of the underlying condition (e.g., neuropathic pain or anxiety). 6 Withdrawal symptoms have distinct characteristics including sudden onset, agitation, disorientation, and severe anxiety that differ from the original indication for treatment.

3127 196873

References

Research

How addictive are gabapentin and pregabalin? A systematic review.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2017

Research

Gabapentin: Abuse, Dependence, and Withdrawal.

The Annals of pharmacotherapy, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Gabapentin Controlled Substance Classification

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Gabapentin Dependence and Misuse

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.